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A B S T R A C T
Background
Acute diarrhoea is a leading cause of death for children under five years of age. Most deaths are caused by excessive fluid and electrolyte
losses. Racecadotril is an anti-secretory drug that has been used for acute diarrhoea in children as an adjunct to oral rehydration therapy.
Objectives
To assess the eIicacy and safety of racecadotril for treating acute diarrhoea in children under five years of age.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL,
published in the Cochrane Library Issue 3, March 2019); MEDLINE; Embase; LILACS; ClinicalTrials.gov; and the World Health Organization
International Clinical Trials Registry Platform (WHO ICTRP), up to 4 March 2019, for clinical trials regardless of publication language or
status.
Selection criteria
Randomized controlled trials (RCTs) that compared racecadotril to placebo or no intervention in addition to standard care (oral rehydration
therapy) in children under five with acute diarrhoea. The primary outcomes were failure of oral rehydration, duration of diarrhoea, and
number of stools. The secondary outcomes were stool output, length of the hospital stay, and adverse events.
Data collection and analysis
Two review authors independently assessed trial eligibility, extracted the data and assessed risk of bias. We presented dichotomous
data with risk ratios (RR) and continuous data with mean diIerence (MD) or standardized mean diIerence (SMD). Where appropriate, we
combined trials with meta-analysis and used a random-eIects model if there was significant heterogeneity (I2 ≥ 50%). We assessed the
certainty of the evidence using the GRADE approach.
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Main results
Seven RCTs with a total of 1140 participants met the inclusion criteria. The trials were carried out on children aged three months to five
years, in outpatient and inpatient facilities from France, Spain, Peru, India, Kenya, and Ecuador. The eIicacy and safety of racecadotril
were compared to placebo or no treatment. Racecadotril may reduce the risk of rehydration failure (RR 0.41, 95% CI 0.13 to 1.23; 2 RCTs,
192 participants; low-certainty evidence). Data on duration of diarrhoea, number of stools in the first 48 hours are insuIicient to reach a
conclusion; stool output in the first 48 hours appears to be lower in the two trials measuring this, although the data is not combinable.
Length of hospital stay was similar in two studies measuring this, and overall there was no evidence that racecadotril increased overall rate
of adverse events (RR 0.90, 95% CI 0.66 to 1.22; 5 RCTs, 688 participants; low-certainty evidence). Most adverse events in the racecadotril
group were mild or moderate.
Authors' conclusions
Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age. Current evidence




All studies incorporated from most recent search
All studies identified during the most recent search (4 Mar, 2019) have been incorporated in the review, and no ongoing studies identified.
P L A I N   L A N G U A G E   S U M M A R Y
Racecadotril to treat children under five years of age with acute diarrhoea
What was the aim of this review?
The aim of this Cochrane Review was to find out whether racecadotril works for children under five years of age with diarrhoea. Cochrane
Review authors collected and analysed all relevant trials to answer this question and included seven trials in this review.
Key messages
Racecadotril may reduce the risk of rehydration failure. We are uncertain whether or not it influences number of bowel movements or
duration of diarrhoea.
What was studied in the review?
Diarrhoea is a leading cause of death in children under five years old, especially in low-income countries. Children who have diarrhoea
oOen suIer from frequent and watery bowel movements, which might cause excessive loss of fluid and electrolytes (dehydration). Fluid
replacement is recommended to prevent and treat dehydration caused by diarrhoea. Racecadotril has been used in addition to fluid
replacement for treating diarrhoea in children, as it reduces release of water and electrolytes into the digestive tract. The drug is supposed
to improve the symptoms of diarrhoea (shorten duration of diarrhoea or reduce the stool frequency) as well as reduce the risk of rehydration
failure. However, it is not clear if racecadotril really works for children with diarrhoea.
What are the main results?
The review authors searched for available trials and included seven trials. The trials were conducted in a total of 1140 children aged from 3
months to 5 years. Children who were given racecadotril were compared to a control group (children who, instead of racecadotril, received
a placebo (a dummy drug that contains no racecadotril) or no drug). The review shows that when children with diarrhoea were given
racecadotril, compared to placebo or no drug:
• racecadotril may reduce the risk of rehydration failure (low-certainty evidence);
• we are uncertain whether or not racecadotril shortens duration of diarrhoea (very low-certainty evidence);
• we are uncertain whether racecadotril influences the number of stools (very low-certainty evidence);
• racecadotril may reduce weight of stool output (low-certainty evidence);
• racecadotril may make little or no diIerence to length of hospital stay for inpatients (low-certainty evidence);
• racecadotril may make little or no diIerence to rates of side-eIect events (low-certainty evidence)
How up to date is this review?
The review authors searched for trials published up to 4 March 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Summary of findings table 1
Racecadotril compared to placebo/no treatment for acute diarrhoea in children
Patient or population: acute diarrhoea in children
Setting: hospital and outpatients
Intervention: racecadotril
Comparison: placebo/no treatment
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Racecadotril may make little or no
difference to length of hospital stay
for inpatients
Adverse events:
number of all types
of adverse events




688 (5 RCTs) ⊕⊕⊝⊝
LOW j,k
Due to risk of bias and
imprecision
Racecadotril may make little or no
difference to rates of adverse events
aDowngraded by 1 for serious risk of bias: both trials have unclear allocation concealment; one study has > 20% loss to follow-up.
bDowngraded by 1 for serious imprecision: a wide 95% CI that includes appreciable benefit (RR < 0.75).
cDowngraded by 1 for serous risk of bias: 1 trial has unclear method of random sequence generation; 3 trials have unclear allocation concealment; 1 trial has > 20% loss to follow-
up; 2 trials have no blinding.
dDowngraded by 2 for very serous inconsistency: inconsistent conclusions on the eIect of the intervention (2 trials concluded that racecadotril might shorten duration of diarrhoea
while 3 with lower overall risk of bias reported no diIerence between 2 groups on this outcome).
eThe certainty of evidence was graded based on 4 studies reporting this outcome. Downgraded by 1 for serious risk of bias: 3 trials have unclear allocation concealment; 2 trials
have no blinding; 2 trials have > 20% loss to follow-up.
fDowngraded by 2 for very serous inconsistency: inconsistent conclusions on the eIect of the intervention (3 trials reported no statistically diIerence between 2 groups in number
of stools within 48 hours while 1 trial reported racecadotril might be eIective for this outcome).
gDowngraded by 1 for serious risk of bias: both trials have unclear method of random sequence generation and unclear allocation concealment; 1 trial has > 20% loss to follow-up.
hDowngraded by 1 for serious imprecision; the total sample size was small (less than 400).
iDowngraded by 2 for serious imprecision; the total sample size was small (less than 400) and no variance is given.
jDowngraded by 1 for serious risk of bias: 2 trials have unclear method of random sequence generation; 4 trials have unclear allocation concealment; 1 trial has no blinding; 3
trials have > 20% loss to follow-up.
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B A C K G R O U N D
Description of the condition
Diarrhoea is defined as the passage of three or more loose or liquid
stools per day (WHO 2017). Acute diarrhoea lasts usually several
hours or days, while persistent diarrhoea has a duration of 14
days or longer. Acute diarrhoea remains a leading cause of death
for children under five years of age. Each year, an estimated 1.7
billion cases of acute diarrhoea occur worldwide among children,
leading to around 525,000 deaths (WHO 2017). Acute diarrhoea is
a common symptom of gastrointestinal infections mostly caused
by a wide range of pathogens, including bacteria, viruses, and
protozoa. However, just a handful of organisms are responsible for
most acute cases of childhood diarrhoea, with rotavirus being the
leading cause of acute diarrhoea among children under five (WHO
1999; WHO 2008). Most deaths from acute diarrhoea are caused
by excessive fluid and electrolyte losses (Tormo 2008), and most
are therefore avoidable provided losses are replaced promptly
by rehydration. Oral rehydration therapy has been recommended
as the essential treatment for acute diarrhoea in children (NICE
2009; UNICEF/WHO 2004). A network meta-analysis reported that
27 diIerent types of treatments or treatment combinations for
children with acute diarrhoea were studied in clinical trials; and it
concluded that zinc, Saccharomyces boulardii combined with zinc,
and smectite combined with zinc showed the best combination of
evidence quality and magnitude of eIect, especially in low- and
middle-income countries (Florez 2018).
Description of the intervention
Racecadotril is an anti-secretory drug that exerts its anti-diarrhoeal
eIects by rapidly hydrolyzing to the active metabolite thiorphan,
which is a powerful and selective inhibitor of the enzyme
enkephalinase (Schwartz 2000). It prevents the degradation of
endogenous enkephalins and thus reduces hypersecretion of water
and electrolytes into the intestinal lumen without interfering with
motility (Primi 1999). Unlike loperamide, racecadotril does not act
on µ-opioid receptors and therefore does not prolong intestinal
transit, nor does it encourage bacterial growth in the small intestine
(Maldonado 2006). Also, unlike the antisecretory drug bismuth
salicylate, racecadotril is not associated with a risk of developing
Reye's syndrome (Abramson 1993).
The World Health Organization (WHO) has recommended oral
rehydration solution and zinc for the routine treatment of acute
diarrhoea in children (WHO 2005). Oral rehydration therapy does
not, however, provide relief of diarrhoeal symptoms, which can be
distressing for both children and their caregivers (Szajewska 2007).
Racecadotril has been used for acute diarrhoea in children as an
adjunct to oral rehydration therapy, especially in Europe, South
America and several Asian countries (Bioprojet Pharma 2007). It
might help improve the success of rehydration by reducing fluid
loss and provide relief on the diarrhoeal symptoms by reducing
stool frequency or shortening the duration of diarrhoea, or both. A
meta-analysis of randomized controlled studies in adults showed
that racecadotril can shorten diarrhoea duration and reduce
number of stools, compared to placebo (CoIin 2014). According to
published studies, it also has good tolerability both in children and
adults, with adverse eIects similar to placebo groups (Alam 2003;
Cézard 2001). A cost-utility analysis from the perspective of a UK
payer found racecadotril as adjuvant therapy was more eIective
and less costly compared to oral rehydration therapy alone for
children's diarrhoea (Rautenberg 2012).
Why it is important to do this review
Although racecadotril has been used in many countries, WHO
and National Institute for Health and Clinical Excellence (NICE)
guidelines have not recommended use of any antidiarrhoeal
drugs in children under five (NICE 2009; WHO 2017). The
ESPGHAN evidence-based guideline, Guarino 2014, mentioned
that racecadotril may be considered in the management of acute
diarrhoea in children but well-designed prospective studies should
be carried out in outpatient children, since outpatients account
for the majority of rotavirus-associated cases of diarrhoea in
children (Parashar 2003). A systematic review covering a small
number of earlier published trials found that racecadotril was
eIective in reducing weight and frequency of stool output as well
as shortening the duration of diarrhoea in children (Szajewska
2007). However, stool output weight, as the primary outcome, has
limited practical value and tends to be influenced by factors such
as food intake and to be contaminated by urine. Two systematic
reviews or meta-analyses concluded that racecadotril was eIective
in children with acute diarrhoea; risk of bias was not assessed
for included trials in those reviews, however (Eberlin 2018; Lehert
2011). In addition, one of the main purposes of using racecadotril
is to prompt correction of water-electrolyte disturbances, and
thus outcomes for evaluating the success of rehydration should
also be included. Previous reviews did not include this outcome
when evaluating the eIicacy of racecadotril (Gordon 2016; Lehert
2011; Szajewska 2007). Although several systematic reviews have
been conducted in order to assess the eIicacy of racecadotril for
children with acute diarrhoea, the benefit of using racecadotril
is still controversial as newly published trials have inconsistent
conclusions on its eIicacy (García 2016; Gharial 2017; Kang 2016a;
Kang 2016b; Sreenivas 2017). An updated systematic review that
carefully assesses risk of bias of available trials and addresses
outcomes both on symptomatic relief and success of rehydration
was needed.
O B J E C T I V E S
To assess the eIicacy and safety of racecadotril for treating acute
diarrhoea in children under five years of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Children less than five years old with uncomplicated acute
diarrhoea, defined as passing loose or watery stools at least three
times in a 24-hour period and lasting less than seven days.
Types of interventions
Intervention
Orally administered racecadotril irrespective of dose, duration, and
interval of administration.
Racecadotril for acute diarrhoea in children (Review)
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Control
Placebo, or no treatment.
Oral rehydration therapy as the standard care should be given to
both intervention and control groups. We also included trials in
which both groups received zinc as an adjunct to oral rehydration
therapy, as it is recommended by the WHO. (UNICEF/WHO 2004)
Types of outcome measures
Primary outcomes
• Failure of oral rehydration, defined as any of the
following: worsening or no improvement of dehydration;
recurring dehydration; need for unscheduled intravenous
fluid infusion; participants initially without dehydration
subsequently developing dehydration; or need for hospital
admission in outpatients.
• Duration of diarrhoea, defined as the time period in days
from randomization or start of treatment to the resolution of
diarrhoea.
• Number of stools, defined as the number of stools or
bowel movements within 48 hours aOer administration of
interventions.
Secondary outcomes
• Stool output: the accumulated weight of stool output within 48
hours, measured by using diapers or others ways.
• Length of hospital stay for inpatients: the time period in
days from randomization or the start of treatment to hospital
discharge for hospitalized patients.
• Adverse events: number of all types of adverse events.
Search methods for identification of studies
We attempted to find all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases: the Cochrane Infectious
Diseases Group Specialized Register; the Cochrane Central Register
of Controlled Trials (CENTRAL, published in the Cochrane Library
issue 3, March 2019); MEDLINE (via OVID, 1966 to 4 March 2019);
Embase (via OVID, 1980 to 4 March 2019); and LILACS (1982 to
4 March 2019), using the search terms detailed in Appendix 1.
We also searched Clinicaltrials.gov and the search portal of the
World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP), to identify ongoing or unpublished trials,
using “diarrh*”, “racecadotril” and “child*” as search terms. All the
search work was up to 4 March 2019.
Searching other resources
We reviewed the citations of existing reviews and clinical
trials obtained by the above methods. We also contacted
individual researchers and pharmaceutical companies for data of
unpublished trials.
Data collection and analysis
Selection of studies
Two review authors (YL and LZ) independently screened the titles
and abstracts of all studies identified by the search strategy and
obtained the full articles for all potentially relevant trials. We
independently assessed the full text using an eligibility form based
on the inclusion criteria. We resolved disagreements by discussion
until consensus was achieved. We scrutinized each of the articles
to ensure that each trial was included only once. We documented
the reasons for excluding trials in the Characteristics of excluded
studies table. We constructed a PRISMA diagram to illustrate the
study selection process.
Data extraction and management
Two review authors (YL and LZ) independently extracted the data
using a pre-designed data collection form. The extracted items
included: 1) authors; 2) year of publication; 3) the country where
the trial was conducted; 4) number of participants randomized into
each group; 5) inclusion and exclusion criteria; 6) interventions in
both groups; 7) dose and duration of racecadotril; 8) outcomes;
9) source of funding. For each treatment arm, we extracted
the number of participants randomized to each group and
the number of analysed participants for each outcome. For
dichotomous outcomes, we extracted the number of participants
experiencing the event in each group of the trial; for continuous
data, we extracted means and standard deviations (median and
interquartile for skewed data). Studies that were published in
languages other than English were translated with the help of
Cochrane Infectious Diseases Group.
Assessment of risk of bias in included studies
Two review authors (YL and LZ) independently assessed the risk
of bias using the Cochrane ‘Risk of bias' tool, which addresses six
specific domains: sequence generation, allocation concealment,
blinding, incomplete outcome data, selective outcome reporting,
and other bias (Higgins 2011). We categorized the judgements as
low, high or unclear risk of bias, and documented reasons for each
judgement. We resolved disagreements by discussion or consulting
methodologists from the Chinese Cochrane Center. We created
plots of risk of bias assessment in Review Manager 5 (RevMan 5)
(Review Manager 5). We contacted authors of included trials for
additional information if needed for risk of bias assessment.
Measures of treatment e;ect
We used risk ratio for dichotomous data and mean diIerence
(standardized mean diIerence if the outcome was reported
on diIerent scales) for continuous data, presenting with 95%
confidence intervals.
Dealing with missing data
We attempted to contact the trial authors when data were
insuIicient or missing. We noted proportions of participants for
whom we could obtain no outcome data, and reported them in a
‘Risk of bias’ table. We dealt with missing data at individual study
and outcome level. We checked the number of children lost to
follow-up and the reasons for missing data in each group. If, in
accordance with the guidance in Guyatt 2011b, the proportion was
less than 20% and meanwhile the reasons and numbers of missing
were balanced in the two groups, we graded the risk of attrition bias
Racecadotril for acute diarrhoea in children (Review)
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as low; otherwise, we graded it as high. We performed sensitivity
analyses based on participants originally assigned to two groups
or reported results from intention-to-treat (ITT) analyses in the
original clinical trials if no meta-analysis was conducted.
Assessment of heterogeneity
We judged clinical heterogeneity based on our knowledge at
patient, intervention, control and outcome level. We used the
I2 statistic to check statistical heterogeneity, considering an I2
value of 50% or greater to denote significant heterogeneity. We
used a fixed-eIect model to synthesize data when heterogeneity
was not significant (I2 < 50%) and a random-eIects model when
heterogeneity was significant (I2 ≥ 50%).
Assessment of reporting biases
We planned to examine publication bias using a funnel plot, and to
use a regression approach to assess funnel plot asymmetry if more
than nine trials reported the same outcome (Egger 1997). However
the number of included trials failed to meet the requirements, so
we did not conduct analysis of reporting bias.
Data synthesis
We conducted meta-analyses using Review Manager 5 (RevMan 5),
and present the results with 95% confidence intervals (CI) (Deeks
2011). For failure of rehydration and adverse eIects, we calculated
the pooled estimate of the risk ratio (RR) between two groups. For
duration of diarrhoea, number of stools, stool output, and length
of hospital stay, we planned to pool the results by calculating the
mean diIerence or standardized mean diIerence. If included trials
reported results using median instead of means, this might indicate
that the data were skewed so we did not combine those results
in meta-analysis (Deeks 2011). We used either a fixed-eIect or
random-eIects model according to the heterogeneity in outcomes
across trials assessed by the I2 statistic test.
Subgroup analysis and investigation of heterogeneity
We expected to conduct subgroup analysis on inpatient versus
outpatient groups, diIerent disease severity groups, rotavirus
versus non-rotavirus groups and diIerent dosage of racecadotril.
Sensitivity analysis
We conducted sensitivity analyses by limiting the analyses to
those with lower overall risk of bias, especially with adequate
randomization, allocation concealment, and blinding. We also
performed sensitivity analyses on binary outcomes based on the
number of participants originally randomized into two groups or
reported results of ITT analyses from original clinical trials for both
continuous and dichotomous outcomes for sensitivity purposes.
Assessment of the certainty of the evidence
We assessed the certainty of the evidence using the GRADE
approach and used the GRADEpro Guideline Development Tool
(GDT) to create the ‘Summary of findings' tables (GRADEpro GDT).
The certainty rating of the studies has four levels: high, moderate,
low, and very low. RCTs are initially categorized as high certainty
but can be downgraded aOer assessment of five aspects: risk of
bias, consistency, directness, imprecision, and publication bias
(Guyatt 2011a). In the GRADE system, high-certainty evidence
denotes that further research is unlikely to change our confidence
in the estimate of eIect; moderate-certainty evidence denotes that
further research is likely to have an important impact on confidence
in the estimate of eIect and may change the estimate; low-certainty
evidence denotes that further research is very likely to have an
important impact on confidence in the estimate of eIect and is
likely to change the estimate; very low certainty evidence denotes
a serious lack of confidence in the eIect estimate (Schünemann
2011). For outcomes for which we could not obtain a single pooled
estimate, we assessed the certainty of evidence based on all trials
that reported the same outcome and presented estimates with
narrative description in the ‘Summary of findings' table (Murad
2017).
R E S U L T S
Description of studies
Results of the search
We identified 213 citations by initial searching of databases and 9
records from clinical trial registry platforms. During study selection
we encountered three non-English articles and obtained help from
the Cochrane Infectious Diseases Group (CIDG) with translating
them into English (Calatayud 2009; Cojocaru 2002; García 2016).
AOer selecting according to inclusion criteria, we included seven
RCTs, involving 1140 participants (Cézard 2001; García 2016; Gharial
2017; [Kang 2016a; Kang 2016b]; Salazar-Lindo 2000; Santos 2009;
Sreenivas 2017). See Figure 1 for a flow diagram of the selection
process.
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Figure 1.   Study flow diagram.
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Included studies
See: Characteristics of included studies
Setting
Two trials were conducted in India ([Kang 2016a; Kang 2016b];
Sreenivas 2017); the rest were conducted in France (Cézard 2001),
Spain (Santos 2009), Peru (Salazar-Lindo 2000), Kenya (Gharial
2017), and Ecuador (García 2016).
Participants
Participants were aged from three months to 5 years. All trials
excluded patients who received antibiotics or other anti-diarrhoeal
drugs during this episode of diarrhoea. Two did not exclude
participants with comorbid diseases or conditions like HIV and
severe malnutrition (Gharial 2017; Santos 2009). Salazar-Lindo
2000 studied only boys to minimize the contamination of stool
by urine in assessment of stool output. Gharial 2017 and [Kang
2016a; Kang 2016b] graded the severity of diarrhoea with the
Vesikari score (Lewis 2011); and Gharial 2017 included participants
with a score greater than 11 (severe) only. Two trials included
outpatients only (García 2016; Santos 2009); while four included
inpatients only (Cézard 2001; Gharial 2017; Salazar-Lindo 2000;
Sreenivas 2017). One trial included both inpatients and outpatients
but reported their results separately (Kang 2016a; Kang 2016b).
Sreenivas 2017 included paediatric ward inpatients but children
with severe diarrhoea were excluded.
Interventions
In Santos 2009 and García 2016, 10 mg of racecadotril was given
every 8 hours for children weighing less than 9 kg, 20 mg every 8
hours for children weighing 9 kg to 13 kg, and 30 mg every 8 hours
for those weighing more than 13 kg. In Gharial 2017, racecadotril
was administered at 10 mg per dose for children below 12 months
of age and 30 mg for those over 12 months of age. In the other
four trials, racecadotril was given three times daily at a dose of 1.5
mg/kg (Cézard 2001; [Kang 2016a; Kang 2016b]; Salazar-Lindo 2000;
Sreenivas 2017).
Comparison
Five trials used placebo as control compared to racecadotril (Cézard
2001; García 2016; Gharial 2017; [Kang 2016a; Kang 2016b]; Salazar-
Lindo 2000), while in the other two, racecadotril was compared
to no treatment in addition to standard therapy (Santos 2009;
Sreenivas 2017).
Outcomes
Two trials reported the primary outcome ‘failure of
rehydration' (García 2016; Sreenivas 2017). All except one —García
2016— reported the outcome ‘duration of diarrhoea'. Two trials
reported the number of outpatients' stools during the first and
second day aOer treatment (García 2016; Santos 2009); and two
reported the number of stools within 48 hours in inpatients
(Gharial 2017; Sreenivas 2017). Three trials reported the weight of
stool output (Cézard 2001; Kang 2016a; Salazar-Lindo 2000). Two
reported the outcome ‘length of hospital stay' (Gharial 2017; Kang
2016a). All except one reported adverse events (Kang 2016a; Kang
2016b).
Funding
Three trials were supported by the pharmaceutical industry
(Gharial 2017; Salazar-Lindo 2000; Santos 2009). García 2016 did
not clearly report source of funding. One failed to report the
source of funding but several authors are from pharmaceutical
industry (Cézard 2001). Kang 2016a and Kang 2016b received
funding from a governmental organization (Swedish International
Development Agency) and Sreenivas 2017 did not receive any
funding for conducting the trial.
Excluded studies
See: Characteristics of excluded studies
Risk of bias in included studies
See Figure 2 and Figure 3 for a summary of risk of bias assessment.
We emailed the authors of included trials for further information
regarding risk of bias but only one replied (Gharial 2017). We were
not able to contact authors from two trials as the email addresses
listed in the articles are no longer valid (Cézard 2001; Salazar-Lindo
2000).
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Figure 2.   'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages
across all included trials.
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Figure 3.   'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial.
 
Allocation
Five trials were at high risk of selection bias: two failed
to report how the random sequence was created (Cézard
2001; Salazar-Lindo 2000); and five did not report if allocation
concealment was conducted (Cézard 2001; García 2016; Salazar-
Lindo 2000; Santos 2009; Sreenivas 2017). Two trials reported
that allocation concealment was achieved by sealed envelopes
with randomization codes given directly to the hospital pharmacy
([Kang 2016a; Kang 2016b]; Gharial 2017).
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Blinding
Two trials were at high risk of performance bias and detection bias
for no blinding (Santos 2009; Sreenivas 2017). Five were reported
as double-blinded placebo-controlled trials (Cézard 2001; García
2016; Gharial 2017; [Kang 2016a; Kang 2016b]; Salazar-Lindo 2000).
Incomplete outcome data
Three trials were at high risk of attrition bias, two due to high loss
to follow-up (> 20%) (Cézard 2001; Santos 2009) and one due to
imbalance in loss to follow-up (García 2016). Four trials were at
low risk of attrition bias (Gharial 2017; [Kang 2016a; Kang 2016b];
Salazar-Lindo 2000; Sreenivas 2017).
Selective reporting
Five trials had unclear risk of reporting bias as it was not reported if
their research protocols were registered or accessible (Cézard 2001;
García 2016; Salazar-Lindo 2000; Santos 2009; Sreenivas 2017). It
was unknown whether all the pre-designed outcomes in those trials
had been reported. Two trials have research protocols registered
on clinical trial registration platforms and reported all pre-designed
outcomes (Gharial 2017; [Kang 2016a; Kang 2016b]).
Other potential sources of bias
Three trials were supported by the pharmaceutical industry
(Gharial 2017; Salazar-Lindo 2000; Santos 2009), and one failed
to report the role of the pharmaceutical company in the trial,
leading to high risk of bias for potential conflict of interest (Salazar-
Lindo 2000). Santos 2009 clearly reported that the pharmaceutical
company was not involved in data collection, analysis and result
interpretation; Gharial 2017 received part of its funding from the
pharmaceutical industry but, as the conclusion did not favour the
company, there was low risk of bias caused by conflict of interest.
One trial failed to report source of funding, but some authors were
from the pharmaceutical industry, causing potentially high risk of
bias (Cézard 2001).
E;ects of interventions
See: Summary of findings for the main comparison Summary of
findings table 1
Failure of rehydration
Two trials reported outcomes that can be categorized into failure of
rehydration (García 2016; Sreenivas 2017). Participants in these two
trials all have mild to moderate diarrhoea, even though Sreenivas
2017 was conducted in an inpatient setting and García 2016 was
conducted in outpatients from the emergency room. One (113
participants) reported that three children from the racecadotril
group and seven from the placebo group received intravenous
fluid therapy due to worsening of dehydration (Sreenivas 2017).
The other trial (79 participants) found that one child from the
racecadotril group and seven from the placebo group were
hospitalized aOer treatment in the emergency room (García 2016).
The pooled analysis showed that there was no significant diIerence
between racecadotril and control group on the rate of rehydration
failure (RR 0.41, 95% CI 0.13 to 1.23, I2 = 0%; 2 trials, 192 participants;
Analysis 1.1; Figure 4). The sensitivity analysis based on the number
of participants originally randomized in two groups does not
change the significance of the result.
 
Figure 4.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 1.1 Failure of rehydration.
 
Duration of diarrhoea
Five trials (867 participants) reported the average duration of
diarrhoea in two groups. Three trials included only inpatients
(Gharial 2017; Salazar-Lindo 2000; Sreenivas 2017); one included
only outpatients (Santos 2009); and one was conducted on
both inpatients and outpatients (Kang 2016a; Kang 2016b). No
pooled analysis was conducted as the outcome was reported
inconsistently with mean or median (Table 1). Overall, three trials
(619 participants) with lower risk of bias reported no significant
diIerence on duration of diarrhoea between two groups (Gharial
2017; [Kang 2016a; Kang 2016b]; Santos 2009); while the other
two (248 participants) showed duration of diarrhoea was shorter in
those receiving racecadotril (Salazar-Lindo 2000; Sreenivas 2017).
Number of stools
Four trials (491 participants) reported number of stools in two
groups. No pooled analysis was conducted across all four trials
as the outcomes were measured with diIerent time period and
were reported inconsistently with mean or median (García 2016;
Gharial 2017; Santos 2009; Sreenivas 2017). Two trials reported the
daily mean number of stools and the pooled analysis shows that
the daily number of stools was not significantly diIerent between
two groups, both at 24 hours (MD −0.24, 95% CI −0.90 to 0.43,
I2 = 36%; 2 trials, 258 outpatients; Analysis 1.2; Figure 5) and 48
hours aOer treatment (MD −0.80, 95% CI −1.87 to 0.27, I2 = 67%; 2
trials, 258 outpatients; Analysis 1.3; Figure 6) (García 2016; Santos
2009). Santos 2009 compared the number of stools at diIerent time
points according to microbiological results (bacterial and viral) of
the stools cultures and found no significant diIerence between
groups at any time of the visits. The trial also conducted a Poisson
linear regression which showed a rapid decline in the number of
stools in both groups without any statistically significant diIerence
by 48 hours aOer the beginning of therapy. Similar results were
obtained in both ITT and per protocol analyses.
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Figure 6.   Forest plot of comparison: 1 Racecadotril versus placebo/no treatment, outcome: 1.3 Number of stools
between 24 to 48 hours.
 
Gharial 2017 (120 inpatients) reported the median number of stools
in the first 48 hours aOer introduction of racecadotril or placebo and
it was five (IQR 3 to 7) in the racecadotril group and five (IQR 2.5 to
7.5) in the placebo group, and the diIerence was not significant (P
= 0.63). However another trial (113 inpatients), with higher overall
risk of bias, reported the mean number of stools within 48 hours
was 10.5 ± 3.2 (SD) in racecadotril group and 15.9 ± 4.6 (SD) in
the control group and the diIerence was significant (P < 0.001)
(Sreenivas 2017).
Stool output
Two trials reported the stool output within 48 hours aOer treatment
(Cézard 2001; Salazar-Lindo 2000).The pooled estimates showed
that stool output was significantly lower in the racecadotril group
than in the placebo group (SMD −0.65, 95% CI −0.88 to −0.41, I2 =
0%; 2 trials, 301 inpatients; Analysis 1.5; Figure 7).
 
Figure 7.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 1.5 Stool output within 48 hours.
 
The subgroup analysis from data of rotavirus-positive children
showed that the stool output was also significantly lower in the
racecadotril group than in the placebo group (SMD −0.83, 95% CI
−1.19 to −0.47, I2 = 0%, 2 trials, 128 inpatients; Analysis 1.5). One
trial also reported that weight of stool output within 24 hours
aOer drug treatment was significantly lower in the racecadotril
group compared to placebo (MD = −5.50, 95% CI −7.71 to −3.29;
1 trial, 167 inpatients; Analysis 1.4; Figure 8). Stool output in the
racecadotril group was significantly lower both in ITT (P = 0.025)
and per protocol analysis (P = 0.015) (Cézard 2001).
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Figure 8.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 1.4 Stool output within 24 hours.
 
Length of hospital stay for inpatients
Two trials (244 participants) reported the median length of hospital
stay in racecadotril and placebo group. Kang 2016a reported that
length of hospital stay was three (IQR 2.4) days in both groups (P =
0.96). Gharial 2017 also found no significant diIerence between two
groups and the duration was 4 (IQR 1.5 to 6) days in the racecadotril
group and 4.5 (1.8 to 6.3) days in the placebo group (P = 0.71).
Adverse e;ects
Five trials (688 participants) reported the overall incidence of
adverse events in two groups (Cézard 2001; García 2016; Gharial
2017; Salazar-Lindo 2000; Santos 2009). The pooled overall rate of
adverse events was 17.4% in the racecadotril group and 18.4% in
the control group (RR 0.90, 95% CI 0.66 to 1.22, I2 = 0%; 5 trials,
688 participants; Analysis 1.6; Figure 9), showing no significant
diIerence between two groups. The sensitivity analysis based on
the number of participants originally randomized in two groups
does not change the significance of the result.
 
Figure 9.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 1.6 Adverse events.
 
The commonly reported adverse events were urticaria and
vomiting, but the latter may be related to the underlying
diarrhoea aetiology. Santos 2009 reported three serious adverse
eIects. One child in the racecadotril group had an elevation in
transaminases (ALT, 957 UI/L; AST, 1357 UI/L) causing one week
of hospitalization, and the transaminases became normalized 3
months later. However, the causality is not clear as a viral infection
was suspected. Two children in the control group were admitted to
hospital for vomiting and dehydration. Salazar-Lindo 2000 reported
four cases of adverse events (two hypokalaemia, one ileus, and
one mild fever) that were considered to be possibly related to
racecadotril, but none of them were considered serious. Sreenivas
2017 (113 participants) reported that six children from the control
group and five from the trial group had serum K+ values of less than
3.5 mmol/L, but none in either group had any electrocardiogram
changes or symptoms and all recovered without any treatment and
had normal serum K+ when repeated aOer 24 hours.
D I S C U S S I O N
Summary of main results
We identified seven RCTs (1140 children under five years old) that
compared the eIicacy and safety of racecadotril to placebo or no
treatment. Trials were conducted in both inpatient and outpatient
settings in countries with diIerent levels of income. Compared
to placebo or no treatment, racecadotril may reduce the risk of
rehydration failure (low-certainty evidence). Data on duration of
diarrhoea, number of stools in the first 48 hours are insuIicient
to reach a conclusion; stool output in the first 48 hours appears
to be lower in the two trials measuring this, although the data
is not combinable. Length of hospital stay was similar in two
studies measuring this, and overall there was no evidence that
racecadotril increased overall rate of adverse events (low-certainty
evidence). Most adverse events in the racecadotril group were mild
or moderate. See Summary of findings for the main comparison.
Overall completeness and applicability of evidence
Although racecadotril is widely used in Europe, Asia, and South
America, only seven trials met the inclusion criteria and were
included in this review. More trials, especially on children from
developing countries, are needed. A key issue that limits the
application of the evidence is the heterogeneity in context, with
trials either examining the inpatient or outpatient setting and as
such focusing on very diIerent outcomes.
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Failure of rehydration is an important outcome that evaluates the
eIect of racecadotril on improving the success of rehydration and
could directly reflect the clinical value of this drug. Other Cochrane
Reviews on children's diarrhoea made failure of rehydration one
of the primary outcomes in their eIicacy assessment (Hahn 2002;
Hartling 2006). However, only two included trials addressed this
outcome (García 2016; Sreenivas 2017). Future trials on this topic
may consider it as an outcome for eIicacy assessment.
The eIicacy of racecadotril might be influenced by the severity of
the disease, and children with more severe diarrhoea may have
better response to treatment. Only two trials measured the severity
of diarrhoea using a score system (Gharial 2017; Kang 2016a), and
only Gharial 2017 applied it to the inclusion criteria. We roughly
stratified participants into two level of severity based on being
inpatients or outpatients. Future trials might use a score system
to measure the severity of diarrhoea and investigate the impact of
disease severity on the eIicacy of racecadotril.
This review only included RCTs for safety assessment, but
observational studies could also provide important data on safety,
especially on reporting serious rare adverse events. Nucera 2006
reported a case of a 3-year-old child (weight: 20 kg) with generalized
oedema, itching, and aphonia aOer a two-day treatment with
racecadotril. He recovered aOer discontinuation of racecadotril and
treatment with methylprednisolone, hydroxyzine, and adrenaline.
Moreno 2009 reported a 12-year-old boy who developed cephalic
pruritus 10 minutes aOer administration of 100 mg of racecadotril.
Simple-blinded controlled oral challenge was conducted with
increasing dose of racecadotril; 15 minutes later the child suIered
a facialis erythema and a generalized urticaria, which illustrated
that racecadotril is related to hypersensitivity. The small sample
size and short duration of follow-up within the included RCTs limits
this review's ability to analyse adverse eIects. Further reviews may
consider including observational studies for safety assessment.
In applying the evidence to clinical practice, the types of patients
should be considered. We only included children under five in the
eIicacy and safety assessment for a single clinical presentation,
leading to a homogeneous data set. However, racecadotril is widely
used in other age groups of children and adults. The results of this
review might not be applicable to other age groups. In addition,
racecadotril has been used for other causes of loose stools, such as
in bacterial infectious diarrhoea, and diarrhoea secondary to other
conditions like chemotherapy, HIV, malnutrition, etc. The results of
this review may not be applicable to those groups of patients.
Certainty of the evidence
See Summary of findings for the main comparison. The certainty
of evidence obtained from current trials ranged from very low to
low. Generally, the quality of trial reporting is higher in recently
published studies than older ones. There has been improvement
with regard to reporting methods of randomization in recent
studies but many still did not report how they performed allocation
concealment. Future studies should also improve transparency on
reporting roles of pharmaceutical companies during the trial if they
receive funding from the industry.
Potential biases in the review process
We used a well-designed search strategy to find clinical studies on
this topic. There were, nevertheless, unpublished data that were
not available to us; and there might also be existing published
studies that were not found by our search strategies. There is
consequently the possibility of bias resulting from incomplete data
for analysis.
We did not find enough trials to test publication bias using funnel
plots. There is, however, a potential for publication bias as some
trials were funded by the pharmaceutical industry and the conflict
of interest might influence published research results.
Agreements and disagreements with other studies or
reviews
Several recently published systematic reviews have evaluated
the eIicacy and safety of racecadotril in children (Eberlin 2018;
Gordon 2016; Lehert 2011). This trial found that racecadotril
might reduce the weight of stool output, which is consistent
with previous reviews, but there are more discrepancies. Our
review found that there is not suIicient evidence to show
racecadotril shortens the duration of diarrhoea or reduces stool
frequency, which is inconsistent with other published reviews
(Eberlin 2018; Gordon 2016; Lehert 2011). This might mainly be
due to diIerent trials being included in the analysis. Lehert 2011
included mostly earlier trials which tend to report significant
results on these outcomes. Also, Lehert 2011 was an analysis of
individual patient data and included data from five additional
studies compared to this review (Calatayud 2009; Cojocaru 2002;
Gutiérrez-Castrellón 2010; Melendez-Garcia 2007; Savitha 2006).
We excluded Calatayud 2009 and Cojocaru 2002 from this review
for being non-randomized studies. We excluded Melendez-Garcia
2007 as the intervention in the control group was kaolin/pectin.
We also excluded the unpublished study, Gutiérrez-Castrellón 2010,
because some information in the study report we obtained might
not be accurate and we failed to obtain further explanation from
the author. For example, it reported that non-dehydrated children
have much longer disease duration than dehydrated children in the
results, which is contrary to common sense; and Chi2 test was used
for stool frequency which was, in fact, reported as a continuous
variable. Also, the eIect size reported in this study was much bigger
than other studies, which brings great heterogeneity and might
seriously bias the pooled estimates. We do not have access to data
of the unpublished study Savitha 2006, which was included by
another meta-analysis (Lehert 2011). Compared to Gordon 2016,
we did not include Gutiérrez-Castrellón 2010 for the same reasons
above. Compared to Eberlin 2018, we did not search for and include
RCTs published in Chinese medical journals, as many of them were
found not to be RCTs (Wu 2009).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Racecadotril seems to be a safe drug but has little benefit in
improving acute diarrhoea in children under five years of age.
Current evidence does not support routine use of racecadotril in
management of acute diarrhoea in children under five outside of
the context of placebo-controlled RCTs.
Implications for research
More RCTs with good study design, reporting quality, and larger
sample size are still needed if this drug is to be further investigated
as an option. Further trials may consider failure of rehydration
as an outcome for evaluating eIicacy of racecadotril. They might
also stratify participants based on diIerent level of disease severity
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using more direct approaches, such as a severity scoring system,
and investigate the impact of disease severity on eIicacy.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomized, double-blinded, placebo-controlled trial
Length of follow-up: till recovery
Participants Number: 168
Inclusion criteria:
Children of both genders aged 3 months to 4 years who had watery diarrhoea (3 or more watery stools
per day) of less than 72 hours' duration.
Before inclusion, each patient had to pass at least 1 watery stool at the hospital.
Exclusion criteria:
Patients who had chronic diarrhoea, a weight-for-age deficit of 20% or more of National Center for
Health Statistics standards, or a systemic illness or had received an antibiotic, antidiarrhoeal drug, or
acetylsalicylic acid within the preceding 48 hours.
Missing data: 47 participants
Interventions Group 1: 86 received racecadotril additional to oral rehydration
Group 2: 82 received placebo additional to oral rehydration
Racecadotril was given 1.5 mg/kg of body weight, orally every 8 hours.
Outcomes • Stool output in the first 48 hours. Stool weight was measured every 12 hours for the first 48 hours by
subtracting the weight of pre-weighed diapers from that of used diapers.
• Stool output during the first 24 hours
• Na/K ratio of urine
• Duration of diarrhoea. The time to recovery was analysed using Kaplan–Meier curves
• Number and characteristics of stools.
• Tolerability
Notes Location: France
Source of funding was not reported, but some of the authors were from the pharmaceutical industry.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of random sequence generation was not reported
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Cézard 2001 
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Low risk Double-blinded; both drug treatments were given as granules of the same ap-
pearance and taste
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk The total amount of attrition was 28% (more than 20%). The number of loss to




Unclear risk The trial protocol is not available. It was unknown if outcomes were selectively
reported.





Methods Randomized, double-blinded, placebo-controlled trial
Length of follow-up: 3 days
Participants Number: 92
Inclusion criteria:
Children aged 3 months to 36 months with acute diarrhoea (less than 14 days' duration) without dehy-
dration or with mild to moderate dehydration. Diarrhoea was defined as at least 3 stools with a change
in the consistency.
Exclusion criteria:
Failed to tolerate oral administration; previous administration of drugs that might interact with
racecadotril, antibiotics or other therapy for diarrhoea; children with ostomies or with short gut syn-
drome.
Missing data: 13 children
Interventions Group 1: 46 children were randomized to receive oral rehydration solution plus racecadotril;
Group 2: 46 children were randomized to receive oral rehydration solution plus placebo
Racecadotril was given 10 mg for children with a weight under 9 kg, 20 mg for children with a weight of
9 to 13 kg, and 30 mg for patients with a weight of 14 to 27 kg, every 8 hours for 72 hours.
Outcomes • Number of stools
• Consistency of stools
• Need for another emergency room service or primary care consultation
• Admission to hospital
• Compliance
• Participants completing the trial
• Cure
Notes Location: Ecuador
Source of funding: unclear
García 2016 
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Baseline imbalance in the age of the groups (P = 0.043)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Using the site www.randomization.com which generated groups “A” and “B”.
The list was displayed.
Allocation concealment
(selection bias)





Low risk Patients and personnel in the hospital were blinded.
Capsules were identical in shape and colour.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





High risk 45/46 patients completed the trial in the intervention group; 34/46 patients in
the control group completed the trial (loss to follow-up > 20%); reason for loss
to follow-up: did not respond to phone call; no intention-to-treat analysis.
Selective reporting (re-
porting bias)
Unclear risk No information about research protocol




Methods Randomized, double-blinded, placebo-controlled trial
Length of follow-up: not reported
Participants Number: 120
Inclusion criteria:
Children aged 3 to 60 months with acute diarrhoea, as evidenced by a Vesikari score of > 11
Exclusion criteria:
Children who had severe vomiting; those with a clinical diagnosis of dysentery or a known diagnosis of
liver or renal failure; children who had prescriptions of probiotics or any other antidiarrhoeal medica-
tion.
Missing data: 9 participants
Interventions Group 1: 60 children received racecadotril additional to oral rehydration or intravenous rehydration
and zinc
Group 2: 60 children received oral rehydration or venous rehydration and zinc
They received either intravenous fluids as per WHO plan C (30 mL/kg followed by 70 mL/kg over 1 and
5 hours, respectively, in infants and over 30 min and 2.5 hours for those over 12 months of age) or low
Gharial 2017 
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osmolality oral rehydration solution as per WHO plan B (75 mL/kg over 4 hours). Zinc was prescribed at
10 to 20 mg/day.
The test arm received racecadotril at a dose recommended by the manufacturer: 10 mg per dose for
children below 12 months of age and 30 mg for those over 12 months of age.
Outcomes • Number of stools in the first 48 hours after introduction of the drug. The difference in the median
number of stools on intention-to-treat analysis revealed no statistically significant difference.
• Duration of inpatient stay. This was measured as the number of days from the start of the medication
to the day of discharge as determined by the attending physician.
• Duration of illness. This was defined as the duration from the time of introduction of the drug to the
appearance of ≤ 3 formed stools in 24 hours.
• Adverse events associated with racecadotril.
Notes Location: Kenya
The trial received part of its funding from pharmaceutical industry.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Not reported in the article. We contacted the author for additional informa-
tion. The allocation of children was concealed from the primary researcher as
it was carried out by the trial pharmacist; and randomization of each child and






Low risk The medication and placebo were packed in tamper-proof brown bags, sealed
and labelled by a trial pharmacist based oI-site.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk The loss to follow-up was balanced across the 2 groups, with 5/60 lost from
the intervention and 4/60 from the control group. The total amount of attrition
was less than 20%.
Selective reporting (re-
porting bias)
Low risk The trial was registered in Pan African Clinical Trial Registry (PACTR ) and all
outcomes from the protocol were reported.
Other bias Low risk Received part of its funding from pharmaceutical industry but the conclusion




Methods Randomized, double-blinded, placebo-controlled trial
Length of follow-up: not reported
Participants Number: 130
Kang 2016a 
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Inclusion criteria:
Children aged 3 to 59 months with acute diarrhoea (≥ 3 episodes of loose, watery stools in last 24 hours
for less than 3 days); the trial physician recommended hospitalization for management of diarrhoea
(inpatient trial).
Exclusion criteria:
Children with weight less than 5 kg, with severe co-existing diseases, severe malnutrition, chronic diar-
rhoea, or with blood and mucus in stool.
Children received antibiotics, probiotics, steroids, herbal medicines, antiemetics, anti-motility or other
treatment of unknown nature.
Missing data: 6 participants
Interventions Group 1: 65 children received racecadotril additional to WHO standard of care.
Group 2: 65 children received placebo additional to WHO standard of care.
Outcomes • Median duration of diarrhoea. Defined as the time from onset of diarrhoea to the time of resolution,
identified as the time of the last abnormal stool or the start of a 12-hour period with no stool. This was
recorded by a trial nurse in the hospital and by mother’s recall during the field worker’s visit in the
community-based trial
• Diarrhoeal stool volume
• Rehydration requirement
• Presence of vomiting after administering the drug or placebo
Notes Location: India
Source of funding: Swedish International Development Agency (governmental organization)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Individual randomization codes were generated by a statistician not associat-
ed with this trial
Allocation concealment
(selection bias)






Low risk Double-blinded. The hospital pharmacy provided identically packed trial drug
or placebo
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk The loss to follow-up was balanced across the 2 groups, with 4/65 lost from
the intervention and 2/65 from the control group. The total amount of attrition
was less than 20%
Selective reporting (re-
porting bias)
Low risk The trial was registered and all important outcomes were reported
Other bias Low risk Not funded by pharmaceutical industry
Kang 2016a  (Continued)
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Methods Randomized, double-blinded, placebo-controlled trial
Length of follow-up: not reported
Participants Number: 199
Inclusion criteria:
Children aged 3 to 59 months with acute diarrhoea (≥ 3 episodes of loose, watery stools in last 24 hours
for less than 3 days); the trial physician recommended management of diarrhoea at home.
Exclusion criteria:
Children with weight less than 5 kg, with severe co-existing diseases, severe malnutrition, chronic diar-
rhoea, or with blood and mucus in stool.
Children received antibiotics, probiotics, probiotics, steroids, herbal medicines, antiemetics, an-
ti-motility or other treatment of unknown nature.
Missing data: 3 patients
Interventions Group 1: 102 children received racecadotril additional to WHO standard of care.
Group 2: 97 children received placebo additional to WHO standard of care.
Outcomes • Median duration of diarrhoea. Defined as the time from onset of diarrhoea to the time of resolution,
identified as the time of the last abnormal stool or the start of a 12-hour period with no stool. This was
recorded by a trial nurse in the hospital and by mother’s recall during the field worker’s visit in the
community-based trial.
• Presence of vomiting after administering the drug or placebo.
• History of day care or hospital visit, or both, during the period of observation.
Notes Location: India
Source of funding: Swedish International Development Agency (governmental organization)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Individual randomization codes were generated by a statistician not associat-
ed with this trial
Allocation concealment
(selection bias)






Low risk Double-blinded. The hospital pharmacy provided identically packed trial drug
or placebo
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk The loss to follow-up was balanced across the 2 groups, with 3/102 lost from
the intervention and 0/97 from the control group. The total amount of attrition
was less than 20%
Kang 2016b 
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Selective reporting (re-
porting bias)
Low risk The trial was registered and all important outcomes were reported




Methods Randomized, double-blind, placebo-controlled trial
Length of follow-up: 5 days
Participants Number: 135
Inclusion criteria:　
Boys aged 3 to 35 months who were hospitalized for dehydration, having acute watery diarrhoea for 5
days or less.
Exclusion criteria:
Boys with blood in the stool, severe dehydration, or any serious concomitant illness.
Boys treated with antibiotics, other anti-diarrhoeal drugs, or aspirin.
Boys had blood in their stools during the first 24 hours.
Missing data: 23 participants
Interventions Group 1: 68 received racecadotril additional to oral rehydration
Group 2: 67 received placebo additional to oral rehydration
Racecadotril was given 1.5 mg/kg of body weight, orally every 8 hours.
Outcomes • Stool output in the first 48 hours. Stool were collected with pre-weighed diapers; care was taken to
ensure that stools were collected separately from urine.
• Total stool output.
• Duration of diarrhoea. The assessment was made at the time of recovery or at the end of 5 days, if the
child had not recovered by this time.
• Total intake of oral rehydration solution.
Notes Location: Peru
Source of funding: supported by the pharmaceutical industry but failed to report the role of the phar-
maceutical company during the trial
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of random sequence generation was not reported
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Salazar-Lindo 2000 
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Low risk Double-blinded; both treatments were administered as saccharose-containing
powders of identical appearance and taste.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk The loss to follow-up was balanced across the 2 groups, with 9/68 lost from the
intervention and 14/67 from the control group. The total amount of attrition
was less than 20%.
Selective reporting (re-
porting bias)
Unclear risk The trial protocol is not available. It was unknown if outcomes were selectively
reported.
Other bias High risk The trial was supported by the pharmaceutical industry but failed to report the





Length of follow-up: 7 days
Participants Number: 179
Inclusion criteria:
Children aged 3 to 36 months with acute gastroenteritis
Exclusion criteria:
Patients requiring hospitalization, with more than 7 days of symptoms, allergic to any of the compo-
nents of the drug, and receiving drugs that may interact with racecadotril, such as antibiotics, salicy-
lates, or other anti-diarrhoea drugs.
Missing data: 46 participants
Interventions Group 1: 88 received racecadotril additional to oral rehydration
Group 2: 91 received oral rehydration only
The doses of racecadotril were: 10 mg every 8 hours for children weighing less than 9 kg; 20 mg every 8
hours for children weighing 9 to 13 kg; 30 mg every 8 hours for children weighing more than 13 kg.
Outcomes • Duration of diarrhoea.
• Number of bowel movements within 24 hours. Parents or caregivers were provided with a notebook
to record the time of each bowel movement.
• Number of bowel movements between 24 and 48 hours.
• Treatment adherence. Therapeutic adherence was evaluated based on the number of doses received
in 48 hours of treatment: good compliance was defined as when the patients received 75% or more
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Supported by pharmaceutical company who provided funds for monitoring process, statistical analy-
sis, and trial drugs.
The sponsor participated in the trial design but did not participate in the collection, analysis, or inter-
pretation of data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization of each treatment group was performed using a computer pro-









High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Loss to follow-up was 25.7% (more than 20%). The number of participants lost
to follow-up was balanced in two groups but it was not reported if the reasons
for loss to follow-up was also balanced in two groups.
Selective reporting (re-
porting bias)
Unclear risk The trial protocol is not available
Other bias Low risk The sponsor participated in the trial design but did not participate in the col-





Length of follow-up: not reported
Participants Number: 117
Participants were hospitalized but those with severe dehydration were excluded
Inclusion criteria:
Patients aged between 3 months and 5 years with acute watery diarrhoea with duration fewer than 7
days were selected for the trial.
Exclusion criteria:
Subjects were excluded if they had persistent vomiting > 3 episodes/h, severe dehydration, or any se-
rious concomitant illness including HIV seropositive status and severe malnutrition, blood in stool, re-
ceived an antibiotic or any antidiarrhoeal drug within the preceding 48 hours.
Missing data: 4 participants
Sreenivas 2017 
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Interventions Group 1: 55 received racecadotril additional to oral rehydration
Group 2: 62 received oral rehydration only
Racecadotril was given at a dose of 1.5 mg/kg/day 8 hourly. A uniform dose of 20 mg of elemental zinc
was given to all children in both the groups. All the subjects were given breastfeeding, milk and soO
food in accordance with WHO recommendations that diet be maintained during treatment of diarrhoea
to prevent nutritional disturbance.
Outcomes • Stool frequency during first 48 hours
• Total volume of ORS consumed until the cure of diarrhoea





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk The loss to follow-up was balanced across the 2 groups, with 2/55 lost from




Unclear risk Registration of the protocol was not mentioned in the article and the trial pro-
tocol was not available.
Other bias Low risk No funding from the pharmaceutical industry
Sreenivas 2017  (Continued)
Abbreviations: RCT: randomized controlled trial.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Calatayud 2009 Observational study
Chacón 2010 Observational study
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Study Reason for exclusion
Cojocaru 2002 Not an RCT
Melendez-Garcia 2007 The control agent is kaolin/pectin
Michael 2014 Observational study
NCT03463512 Children aged from 3 months to 17 years
Rautenberg 2012 Cost effectiveness study, not an RCT
Tiholova 2010 Only abstract available; observational study
Torrez 2013 Only abstract available. 52% failed to complete the treatment
Turck 1999 Racecadotril was compared with loperamide
Abbreviations: RCT: randomized controlled trial.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods RCT
Participants Children aged 2 to 36 months with acute watery diarrhoea
Interventions Racecadotril + rehydration therapy versus rehydration therapy only
Outcomes Duration of symptoms and signs; incidence of adverse reaction





Participants Infants aged 1 to 24 months with acute diarrhoea
Interventions Racecadotril
Outcomes Stool output, duration of diarrhoea, percentage of need for intravenous fluids for rehydration, per-
centage of adverse events, frequency of stools/day, frequency of liquid or semi-liquid stools/day.




Methods Randomized, open-label, parallel-group study
Participants Children aged 1 months to 5 years with acute diarrhoea
IRCT201607131264N8 
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Interventions Serum therapy + racecadotril (1.5 mg per kg, 3 doses/day for 5 days or when no diarrhoea) versus
serum therapy only
Outcomes Duration of diarrhoea; frequency of diarrhoea; duration of hospital stay
Notes Conducted in Iran





Participants Children aged 3 to 60 months with acute diarrhoea
Interventions Racecadotril + rehydration therapy versus placebo + rehydration therapy
Outcomes Diarrhoea duration
Notes Data was not found
Savitha 2006 
Abbreviations: RCT: randomized controlled trial.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Racecadotril versus placebo/no treatment





Statistical method Effect size
1 Failure of rehydration 2 192 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.13, 1.23]
2 Number of stools within 24 hours 2 258 Mean Difference (IV, Fixed, 95%
CI)
-0.24 [-0.90, 0.43]
3 Number of stools between 24 to 48 hours 2 258 Mean Difference (IV, Random,
95% CI)
-0.80 [-1.87, 0.27]
4 Stool output within 24h 1 167 Mean Difference (IV, Fixed, 95%
CI)
-5.5 [-7.71, -3.29]
5 Stool output within 48h 2   Std. Mean Difference (IV, Fixed,
95% CI)
Subtotals only
5.1 Stool output within 48 hours (all patients) 2 301 Std. Mean Difference (IV, Fixed,
95% CI)
-0.65 [-0.88, -0.41]
5.2 Stool output within 48 hours (ro-
tavirus-positive patients)
2 128 Std. Mean Difference (IV, Fixed,
95% CI)
-0.83 [-1.19, -0.47]
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Statistical method Effect size





Analysis 1.1.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 1 Failure of rehydration.
Study or subgroup Racecadotril Placebo/no
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
García 2016 1/45 3/34 34.23% 0.25[0.03,2.32]
Sreenivas 2017 3/53 7/60 65.77% 0.49[0.13,1.78]
   
Total (95% CI) 98 94 100% 0.41[0.13,1.23]
Total events: 4 (Racecadotril), 10 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=1.59(P=0.11)  
Favours racecadotril 1000.01 100.1 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Racecadotril versus placebo/
no treatment, Outcome 2 Number of stools within 24 hours.
Study or subgroup Racecadotril Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
García 2016 45 4.1 (2.6) 34 5.1 (3.4) 23.61% -1[-2.37,0.37]
Santos 2009 88 4.6 (2.7) 91 4.6 (2.5) 76.39% 0[-0.76,0.76]
   
Total *** 133   125   100% -0.24[-0.9,0.43]
Heterogeneity: Tau2=0; Chi2=1.56, df=1(P=0.21); I2=35.83%  
Test for overall effect: Z=0.69(P=0.49)  
Favours racecadotril 21-2 -1 0 Favours control
 
 
Analysis 1.3.   Comparison 1 Racecadotril versus placebo/no
treatment, Outcome 3 Number of stools between 24 to 48 hours.
Study or subgroup Racecadotril Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
García 2016 45 2.7 (1.5) 34 4.1 (2.7) 45.35% -1.4[-2.4,-0.4]
Santos 2009 88 3.8 (2.4) 91 4.1 (2.7) 54.65% -0.3[-1.05,0.45]
   
Total *** 133   125   100% -0.8[-1.87,0.27]
Heterogeneity: Tau2=0.4; Chi2=3, df=1(P=0.08); I2=66.64%  
Test for overall effect: Z=1.46(P=0.14)  
Favours racecadotril 42-4 -2 0 Favours control
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Analysis 1.4.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 4 Stool output within 24h.
Study or subgroup Racecadotril Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Cézard 2001 85 10.5 (7.4) 82 16 (7.2) 100% -5.5[-7.71,-3.29]
   
Total *** 85   82   100% -5.5[-7.71,-3.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.87(P<0.0001)  
Favours racecadotril 2010-20 -10 0 Favours control
 
 
Analysis 1.5.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 5 Stool output within 48h.
Study or subgroup Racecadotril Placebo/no
treatment
Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.5.1 Stool output within 48 hours (all patients)  
Cézard 2001 84 9.3 (11) 82 15.2 (8.1) 55.5% -0.61[-0.92,-0.3]
Salazar-Lindo 2000 68 92 (99) 67 170 (122.8) 44.5% -0.7[-1.04,-0.35]
Subtotal *** 152   149   100% -0.65[-0.88,-0.41]
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=5.46(P<0.0001)  
   
1.5.2 Stool output within 48 hours (rotavirus-positive patients)  
Cézard 2001 24 8.5 (7.8) 31 19.4 (14.5) 42.14% -0.89[-1.45,-0.33]
Salazar-Lindo 2000 34 105 (99) 39 195 (124.9) 57.86% -0.78[-1.26,-0.31]
Subtotal *** 58   70   100% -0.83[-1.19,-0.47]
Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%  
Test for overall effect: Z=4.47(P<0.0001)  
Test for subgroup differences: Chi2=0.69, df=1 (P=0.41), I2=0%  
Favours racecadotril 10.5-1 -0.5 0 Favours control
 
 
Analysis 1.6.   Comparison 1 Racecadotril versus placebo/no treatment, Outcome 6 Adverse events.
Study or subgroup Racecadotril Placebo/no
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cézard 2001 9/84 9/82 12.7% 0.98[0.41,2.34]
García 2016 13/45 15/34 27.36% 0.65[0.36,1.19]
Gharial 2017 14/60 14/60 22.97% 1[0.52,1.91]
Salazar-Lindo 2000 7/68 5/67 8.03% 1.38[0.46,4.13]
Santos 2009 18/94 19/94 28.95% 0.95[0.53,1.69]
   
Total (95% CI) 351 337 100% 0.9[0.66,1.22]
Total events: 61 (Racecadotril), 62 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=1.87, df=4(P=0.76); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Favours racecadotril 1000.01 100.1 1 Favours control
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A D D I T I O N A L   T A B L E S
 




Santos 2009 179 4.0 (2.1)a 4.7 (2.2)a 0.15Outpa-
tients
Kang 2016b 196 2 (2, 4)b 2 (2, 4)b 0.88
Salazar-Lindo 2000
(rotavirus-positive)
73 1.2c 2.2c < 0.001
Salazar-Lindo 2000
(rotavirus-negative)
62 1.2c 3c < 0.001
Gharial 2017 120 3 (2, 4)b 2 (1, 3)b 0.77
Kang 2016a 124 1.1 (0.6, 1.8)b 1.0 (0.7, 1.9)b 0.57
Inpatients
Sreenivas 2017 113 1.6 (0.3)a 2.1 (0.6)a < 0.001
Table 1.   Average duration of diarrhoea in two groups  (Continued)
aMean (standard deviation).
bMedian (interquartile range).
cMedian without reporting interquartile range.
 
 
A P P E N D I C E S




CIDG SR1 CENTRAL MEDLINE2 Embase2 LILACS2
1 Diarrh* Diarrh* ti, ab Diarrh* ti, ab Diarrh* ti, ab Diarrh$






3 Child* Gastroenteritis ti, ab Gastroenteritis ti, ab Acute gastroenteritis
[Emtree]
Child$
4 Infant* Racecadotril* Racecadotril* Racecadotril* Infant$





6 Pediatr* Child* Child* Child* Pediatr$
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7 Toddler* Infant* Infant* Infant* Toddler$
8 3-7/OR Toddler* Toddler* Toddler* 3-7/OR
9 1 AND 2 AND
8
Pediatr* Pediatr* Pediatr* 1 AND 2 AND
8
10 — Paediatr* Paediatr* Paediatr* —
11 — 1 OR 2 OR 3 1 OR 2 OR 3 1 OR 2 OR 3 —
12 — 4 OR 5 4 OR 5 4 OR 5 —
13 — 6-10/OR 6-10/OR 6-10/OR —
14 — 11 AND 12 AND 13 11 AND 12 AND 13 11 AND 12 AND 13 —
  (Continued)
 
1Cochrane Infectious Diseases Group Specialized Register.
2Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration (Lefebvre 2011).
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the published protocol, Liang 2011, we stated that we intended to include trials from Chinese databases in the eIicacy assessment.
However, as those articles are potentially at higher risk of bias, we decided to exclude trials published in those databases.
We also planned to include quasi-RCTs, but we excluded these from the full review as more RCTs have been published and quasi-RCTs
might be subject to higher risk of bias.
We planned to search the Index to the Index to Scientific & Technical Proceedings (ISTP) for conference abstracts, but this database became
unavailable to us aOer protocol publication.
We used the GRADE approach to assess the certainty of the evidence and constructed ‘Summary of findings' tables and conducted ITT
analyses for sensitivity analysis for dichotomous outcomes in the review.
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